id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-280023-r3qgdgeu	Dipasquale, Valeria	Challenges in paediatric inflammatory bowel diseases in the COVID-19 time	2020-04-08		.txt	text/plain	1064	56	42	The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first reported in China in December 2019, now involves the whole world [1 , 2] . Currently no cases of IBD patients infected by SARS-CoV-2 have been reported. As the risk of infections is generally higher in case of combination therapy (biologics plus immunomodulators) in adult and paediatric patients with IBD [6 , 7] , caution should be used with this therapeutic strategy during the COVID-19 epidemic. In conclusion, while waiting for more specific data concerning the risk of COVID-19 in children with IBD and, more generally, in paediatric patients on immunosuppressive therapy, it seems reasonable to carefully weigh the risks/benefits ratio of treatment with immunomodulators and biologics, especially in areas of high infection rate or outbreaks. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China	./cache/cord-280023-r3qgdgeu.txt	./txt/cord-280023-r3qgdgeu.txt